Autologous stem cells cut insulin requirements in type 2 diabetes

07/1/2013 | Medical News Today

A study in Cell Transplantation found type 2 diabetes patients who received autologous bone marrow stem cells required lower insulin doses compared with those in the control group. Longer-duration studies with a larger number of participants will be needed to establish the efficacy of stem cell treatment in diabetes, researchers said.

View Full Article in:

Medical News Today

Published in Brief:

SmartBrief Job Listings for Health Care